4.7 Article

β-1,3-Glucan reverses aflatoxin B1-mediated suppression of immune responses in mice

期刊

LIFE SCIENCES
卷 152, 期 -, 页码 1-13

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2016.03.030

关键词

Aflatoxin B-1; beta-1,3-Glucan; Immunomodulation; Cytokines; Lymphocyte subsets

资金

  1. Deanship of Scientific Research at King Saud University through the research group project [RGP-VPP-120]

向作者/读者索取更多资源

Aflatoxin B-1 (AFB(1)) is immunotoxic to animals and is a suspected immunosuppressant in humans. beta-1,3-Glucan (BG) consists of glucose polymers and has a variety of stimulatory effects on the immune system. In this study, we investigated the role of BG on the expression of phenotypic markers and cytokine secretion in mice exposed to AFB(1). We treated animals with BG (150 mg/kg, p.o., once daily) for 7 days beginning at the onset of AFB(1) exposure. Exposure of animals to AFB(1) alone (1250 mu g/kg, p.o, once daily) for 7 days resulted in a decrease in the percentages of lymphocyte subsets (CD4(+), GITR(+), CD8(+), TCR beta(+), CD3(+), Foxp3(+), CD4(+) Foxp3(+), and CD127(+)) as compared to an normal control (NC). However, both BG alone and BG given in conjunction with exposure to AFB(1) significantly increased the percentages of these lymphocyte subsets in blood. We also observed that mice exposed to AFB(1) showed reduced IL-2, TNF-alpha, IL-17, and IFN-gamma production in the spleen and serum. In contrast, oral administration of BG alone and in conjunction with AFB(1) exposure augmented the levels of these cytokines. Moreover, this findingwas confirmed through RT-PCR andwestern blot analysis ofmRNA and protein expression in the spleen. Altogether, it can be concluded from these studies that BG enhances the responses of lymphocyte subsets, including cytokine production, even when given following exposure to AFB(1) immunotoxin. These data demonstrate that BG carries out its immunomodulating activity by regulating cytokine production. Our findings also provide a direction for development of specific immunomodulating therapy. (c) 2016 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据